Daniel Allen Gold

Director Daniel Allen Gold sold 1,438,163 shares for $49.4M across 5 trades (June 26–30) at $33.92–$35.28, reducing stake 9.5%

Daniel Allen Gold, as Director of Roivant Sciences, executed 5 separate sales totaling 1,438,163 shares for $49,354,075.76 at blended average price $34.32 during June 26–30, reducing his post-transaction holdings to 13,689,166 shares (9.5% reduction vs pre-transaction 15,127,329 shares). The sales occurred as ROIV is -1.4% from its 52-week high of $35.90 and has appreciated 18.0% over 30 days and 27.1% over 90 days. Notably, Gold's prior 5 trades at ROIV (all sells in February 2026) produced positive 90-day returns of 4.9%–5.9%, meaning the stock rose after each prior sale at this ticker; a 0% well-timed rate over those 5 prior ROIV trades indicates none preceded subsequent declines. Contemporaneously, the company reported trailing-quarter revenue of $1,999,000.00 and full-year net income of -$265,891,000.00 with annual revenue decline of -71.6%, while retaining a $25.5B market cap. The scale of this 1.44M-share liquidation against the backdrop of sustained unprofitability and collapsing revenue—combined with the absence of well-timed prior sell patterns at this ticker—warrants investor attention to whether the sale reflects market window management or operational headwinds below the surface.

Director Gold Daniel Allen sells 1,225,784 shares for $32,658,518.16 at Roivant Sciences (ROIV) over 3 days.

Director Gold Daniel Allen executed 5 separate sales totaling 1,225,784 shares for $32,658,518.16 between February 11–13, 2026, at a blended average price of $26.64—near the 52-week high of $27.67. Post-transaction holdings of 15,127,329 shares represent a 7.5% reduction in position. The sale occurs in a company with material operational headwinds: annual revenue declined 76.7% and quarterly revenue is $1,999,000.00 with a net loss of $-265,891,000.00 (full-year unprofitable). His prior five trades at ROIV (all December 2025 sales) showed mixed 30-day returns (+0.4% to +1.6%), with no measurable 90-day outcomes yet. His cross-ticker track record across 20 prior sales shows an average 90-day return of +1.3% and a 0.00% well-timed rate, indicating his prior sales have generally not preceded declines. The high-price timing and large dollar volume ($32.7M) combined with deteriorating fundamentals merit close monitoring of subsequent quarterly results and insider activity patterns.

ROIV Director Gold Daniel Allen sold 1,694,614 shares (1.69M) for $39,065,213.44 across 5 transactions Dec 16-17 at blended avg $23.05

Director Gold Daniel Allen executed 5 separate sales of 1,694,614 shares (1.69M shares) for $39,065,213.44 at a blended average price of $23.05 on December 16–17, reducing his holdings by 9.4% to 16,353,113 shares. The transaction was executed near the 52-week high of $22.94, with current price at $21.79 suggesting a -5.0% pullback has already occurred post-transaction. Against his cross-ticker track record showing a 0.00% well-timed rate on 16 prior sells, this large disposition occurs against a deteriorating fundamental backdrop: the company reported quarterly revenue of $1,571,000.00 with net income of $-113,519,000.00 and annual revenue contraction of -76.7%, while remaining unprofitable. The scale and timing of this multi-transaction disposition warrant investor scrutiny in the context of the company's operational stress.

Director Daniel Allen sold 1,300,000 shares at $20.23 avg for $26.3M, reducing stake by 6.7% at near 52-week highs

Gold Daniel Allen, a director at Roivant Sciences, executed 4 separate sales totaling 1,300,000 shares for $26,304,500.00 on 2025-11-19, reducing his holdings from 19,347,727 to 18,047,727 shares. The blended average price of $20.23 sits within 5.2% of the 52-week high of $21.32 and reflects the stock's strong 30-day performance of +12.6% and 90-day surge of +69.6%. His prior five sales at ROIV all posted positive 90-day returns (ranging +0.8% to +3.0%), indicating a consistent pattern where shares sold subsequently appreciated rather than declined—a signal that his historical exit timing at this ticker has not preceded downturns. The company operates under significant headwinds: latest quarterly revenue of $1,571,000.00, annual revenue contraction of -76.7%, and a full-year net loss of $-113,519,000.00. The sale at elevated valuations amid deteriorating fundamentals represents a material disposition of ownership during a period of exceptional price momentum.

Director Gold Daniel Allen sells 4,426,000 shares for $51.8M over 3 days at avg $11.71; retains 22.18M shares.

Director Gold Daniel Allen executed 6 separate sales totaling 4,426,000 shares for $51,820,727.30 between 2024-09-24 and 2024-09-26 at prices ranging from $11.62 to $11.82 (blended average $11.71). This represents a -16.6% reduction from his pre-transaction holdings of 26,605,358 shares, leaving him with 22,179,358 shares post-transaction. The sales occurred while the stock was trading -12.3% below its 52-week high of $13.19. His prior 5 trades at ROIV, all executed on 2023-09-28, posted a combined 90-day return of +0.3%, with 0 of 5 reaching well-timed status (negative 90-day return after a sell), suggesting his prior ROIV sales did not precede declines. Given ROIV's fundamentals (revenue $55,132,000.00, net income $95,297,000.00, P/E 1.81, market cap $8.6B), this large liquidation warrants investor attention to understand any strategic or personal circumstances driving the disposition, particularly given the magnitude relative to the director's remaining stake.